Michael A. Curran

12.1k total citations · 3 hit papers
127 papers, 7.0k citations indexed

About

Michael A. Curran is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Michael A. Curran has authored 127 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Immunology, 62 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in Michael A. Curran's work include Cancer Immunotherapy and Biomarkers (52 papers), Immunotherapy and Immune Responses (34 papers) and Immune cells in cancer (29 papers). Michael A. Curran is often cited by papers focused on Cancer Immunotherapy and Biomarkers (52 papers), Immunotherapy and Immune Responses (34 papers) and Immune cells in cancer (29 papers). Michael A. Curran collaborates with scholars based in United States, United Kingdom and China. Michael A. Curran's co-authors include James P. Allison, Hideo Yagita∥, Todd Bartkowiak, Padmanee Sharma, Casey R. Ager, K. Kosmatopoulos, Muhammad Zaeem Noman, Salem Chouaı̈b, Patrick Hwu and Ashvin R. Jaiswal and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Michael A. Curran

120 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

2010 1.5k citations Michael A. Curran, James P. Allison et al. profile →
PD-L1 Expression in Triple-Negative Breast Cancer

2014 1.1k citations Elizabeth A. Mittendorf, Anne V. Philips et al. Cancer Immunology Research profile →
Development of Immunotherapy Combination Strategies in Cancer

2021 231 citations Michael A. Curran et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael A. Curran United States	35	4.0k	3.6k	1.7k	975	867	127	7.0k
Philipp Beckhove Germany	45	4.8k 1.2×	5.0k 1.4×	1.8k 1.1×	709 0.7×	646 0.7×	150	8.4k
Sumit K. Subudhi United States	37	4.0k 1.0×	3.6k 1.0×	1.5k 0.9×	1.8k 1.8×	741 0.9×	108	7.3k
María E. Rodríguez-Ruiz Spain	34	4.0k 1.0×	3.6k 1.0×	1.3k 0.8×	880 0.9×	535 0.6×	89	6.3k
Siwen Hu‐Lieskovan United States	30	6.0k 1.5×	4.3k 1.2×	3.0k 1.8×	1.5k 1.5×	1.1k 1.3×	91	9.0k
Marc Schmitz Germany	46	2.8k 0.7×	3.2k 0.9×	2.0k 1.2×	530 0.5×	440 0.5×	173	6.4k
Hideho Okada United States	54	4.1k 1.0×	5.1k 1.4×	2.8k 1.7×	754 0.8×	1.1k 1.2×	198	8.8k
Mikhail Binnewies United States	14	3.9k 1.0×	4.5k 1.2×	2.6k 1.6×	1.0k 1.0×	1.0k 1.2×	20	8.1k
Kelly Kersten United States	13	3.6k 0.9×	3.7k 1.0×	2.2k 1.3×	1.1k 1.1×	1.1k 1.3×	20	6.9k
Inge Marie Svane Denmark	56	7.2k 1.8×	6.7k 1.8×	3.3k 2.0×	840 0.9×	622 0.7×	385	11.0k
Gunnar Kvalheim Norway	43	2.9k 0.7×	1.8k 0.5×	1.7k 1.0×	571 0.6×	890 1.0×	173	5.5k

Countries citing papers authored by Michael A. Curran

Since Specialization

Citations

This map shows the geographic impact of Michael A. Curran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Curran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Curran more than expected).

Fields of papers citing papers by Michael A. Curran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Curran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Curran. The network helps show where Michael A. Curran may publish in the future.

Co-authorship network of co-authors of Michael A. Curran

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Curran. A scholar is included among the top collaborators of Michael A. Curran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Curran. Michael A. Curran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Chao-Hsien, et al.. (2025). NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in Glioblastoma. Cancer Research Communications. 5(6). 960–972. 3 indexed citations

Deng, Yalan, Zilong Zhao, Yang Zhao, et al.. (2024). LIFR regulates cholesterol-driven bidirectional hepatocyte–neutrophil cross-talk to promote liver regeneration. Nature Metabolism. 6(9). 1756–1774. 7 indexed citations

Liu, Arthur, Jeffrey J. Molldrem, Gheath Alatrash, et al.. (2024). Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia. Cancer Research Communications. 4(3). 911–918. 1 indexed citations

Curran, Michael A., Tingan Li, Derek Heathfield, et al.. (2023). Structural control of bedrock river alignment and morphology in the Fraser Canyon, British Columbia, Canada. Earth Surface Processes and Landforms. 48(15). 3381–3394. 1 indexed citations

Liu, Arthur, Seth T. Gammon, Federica Pisaneschi, et al.. (2023). Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight. 9(1). 7 indexed citations

Patel, Sonia, Monique B. Nilsson, Yan Yang, et al.. (2023). IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clinical Cancer Research. 29(7). 1292–1304. 62 indexed citations

Boudreau, C. Elizabeth, Hinda Najem, Martina Ott, et al.. (2021). Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. Clinical Cancer Research. 27(20). 5528–5535. 34 indexed citations

Rao, Ganesh, Khatri Latha, Martina Ott, et al.. (2020). Anti–PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clinical Cancer Research. 26(17). 4699–4712. 80 indexed citations

Jaiswal, Ashvin R., Arthur Liu, Shivanand Pudakalakatti, et al.. (2020). Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research. 8(11). 1365–1380. 43 indexed citations

10.

Dorta‐Estremera, Stephanie, Gloria Sierra, Courtney Nicholas, et al.. (2018). Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Research. 78(18). 5327–5339. 25 indexed citations

11.

Bartkowiak, Todd, Ashvin R. Jaiswal, Casey R. Ager, et al.. (2018). Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway. Clinical Cancer Research. 24(5). 1138–1151. 70 indexed citations

12.

Buchan, Sarah L., Stephen M. Thirdborough, Vadim Y. Taraban, et al.. (2018). PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity. Clinical Cancer Research. 24(10). 2383–2394. 82 indexed citations

13.

Ager, Casey R., Matthew J. Reilley, Courtney Nicholas, et al.. (2017). Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Cancer Immunology Research. 5(8). 676–684. 146 indexed citations

14.

Tang, Chad, James W. Welsh, Patricia M. de Groot, et al.. (2016). Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research. 23(6). 1388–1396. 251 indexed citations

15.

Mittendorf, Elizabeth A., Anne V. Philips, Funda Meric‐Bernstam, et al.. (2014). PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunology Research. 2(4). 361–370. 1065 indexed citations breakdown →

16.

Curran, Michael A., Theresa L. Geiger, Myoungjoo Kim, et al.. (2013). Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. The Journal of Experimental Medicine. 210(4). 743–755. 134 indexed citations

17.

Duan, Fei, Yun Lin, Cailian Liu, et al.. (2009). Immune Rejection of Mouse Tumors Expressing Mutated Self. Cancer Research. 69(8). 3545–3553. 12 indexed citations

18.

Curran, Michael A. & James P. Allison. (2009). Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors. Cancer Research. 69(19). 7747–7755. 110 indexed citations

19.

Curran, Michael A., Kin-tak Lau, Jochen Hampe, et al.. (1998). Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology. 115(5). 1066–1071. 148 indexed citations

20.

Curran, Michael A., Donald L. Atkinson, K Timothy, et al.. (1993). Locus heterogeneity of autosomal dominant long QT syndrome.. Journal of Clinical Investigation. 92(2). 799–803. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact